Acute Increases in Serum Creatinine After Starting Angiotensin-Converting Enzyme Inhibitor-Based Therapy and Effects of its Continuation on Major Clinical Outcomes in Type 2 Diabetes Mellitus: The ADVANCE Trial
Open accessAbstract
Discontinuation of angiotensin-converting enzyme (ACE) inhibitor is recommended if patients experience ≥30% acute increase in serum creatinine after starting this therapy. However, the long-term effects of its continuation or discontinuation on major clinical outcomes after increases in serum creatinine are unclear. In the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), 11 140 diabetes mellitus patients were randomly assigned to perindopril-indapamide or placebo after a 6-week active run-in period. The current study included 11 066 participants with 2 serum creatinine measurements recorded before and during the active run-in period (3 weeks apart). Acute increase in creatinine was determined using these 2 measurements and classified into 4 groups: increases in serum creatinine of <10%, 10% to 19%, 20% to 29%, and ≥30%. The primary study outcome was the composite of major macrovascular events, new or worsening nephropathy, and all-cause mortality. An acute increase in serum creatinine was associated with an elevated risk of the primary outcome ( P for trend <0.001). The hazard ratios were 1.11 (95% CI, 0.97–1.28) for those with an increase of 10% to 19%, 1.34 (1.07–1.66) for 20% to 29%, and 1.44 (1.15–1.81) for ≥30%, compared with <10%. However, there was no evidence of heterogeneity in the benefit of randomized treatment effects on the outcome across subgroups defined by acute serum creatinine increase ( P for heterogeneity=0.94). Acute increases in serum creatinine after starting perindopril-indapamide were associated with greater risks of subsequent major clinical outcomes. However, the continuation of angiotensin-converting enzyme inhibitor-based therapy reduced the long-term risk of major clinical outcomes, irrespective of acute increase in creatinine. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00145925.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Epidemiologic data suggest no evidence of a threshold for adverse outcomes with a BP level below 115/75 mm Hg.
“Epidemiologic data suggest no evidence of a threshold for adverse outcomes with a BP level <115/75 mm Hg.200”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [200]
The Discussion (p. 6) addresses serum-creatinine changes after ACE inhibitor-based therapy, not an epidemiologic blood-pressure threshold. Searches for the 115/75 mm Hg threshold and for a blood-pressure threshold linked to adverse outcomes found no passage in our copy addressing the claim. (LLM, conf=0.76)
Experimental — accuracy not yet measuredIntensive glycemic control using insulin lowers the risk of microvascular and macrovascular complications in type 1 diabetes.
“Intensive glycemic control with insulin therapy reduces the risk of these complications.200,1122,1123”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [200]
The Study Design and Population section (p. 3) describes intensive glucose control in people with type 2 diabetes using a gliclazide-based regimen, not insulin treatment in type 1 diabetes. The Perspectives section (p. 8) reports benefits of continuing ACE inhibitor–based therapy, not the claimed effect of intensive insulin therapy. Searches for type 1 diabetes, insulin, and microvascular and macrovascular outcomes found no passage addressing the claim. (LLM, conf=0.75)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · see citing works
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,638 · see citing works
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616 · see citing works
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452 · see citing works
Matsushita, K., Coresh, J., Sang, Y., Chalmers, J. P., Fox, C. S., Güallar, E., Jafar, T. H., Jassal, S. K., Landman, G. W. D., Muntner, P., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00040-6 · Cited by 913 · see citing works
Self-citationBakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823 · see citing works
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.46 · Cited by 522 · see citing works
Introduction: <i>Standards of Medical Care in Diabetes—2018</i>
(2018) · Diabetes Care · doi:10.2337/dc18-sint01 · Cited by 472 · see citing works
Holtkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International · doi:10.1038/ki.2011.79 · Cited by 364 · see citing works
Self-citationVardeny, O., Wu, D. H., Desai, A. S., Rossignol, P., Zannad, F. M., Pitt, B., & Solomon, S. D. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.048 · Cited by 275 · see citing works
Testani, J. M., Kimmel, S. E., Dries, D. L., & Coca, S. G. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.963256 · Cited by 245 · see citing works
Apperloo, A. J., de Zeeuw, D., & de Jong, P. E. (1997) · Kidney International · doi:10.1038/ki.1997.111 · Cited by 202 · see citing works
Jose, P. O., Skali, H., Anavekar, N. S., Tomson, C., Krumholz, H. M., Rouleau, J. L., Moyé, L. A., Pfeffer, M. A., & Solomon, S. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010063 · Cited by 196 · see citing works
Available, N. A. N. (2001) · Diabetologia · doi:10.1007/s001250100612 · Cited by 180 · see citing works
Rossignol, P., Cleland, J. G. F., Bhandari, S., Tala, S., Gustafsson, F., Fay, R., Lamiral, Z., Dobre, D., Pitt, B., & Zannad, F. M. (2011) · Circulation · doi:10.1161/circulationaha.111.028282 · Cited by 159 · see citing works
Schmidt, M., Mansfield, K. E., Bhaskaran, K., Nitsch, D., Sørensen, H. T., Smeeth, L., & Tomlinson, L. A. (2017) · BMJ · doi:10.1136/bmj.j791 · Cited by 157 · see citing works
Clase, C. M., Barzilay, J. I., Gao, P., Smyth, A., Schmieder, R. E., Tobe, S. W., Teo, K. K., Yusuf, S., & Mann, J. F. E. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.038 · Cited by 84 · see citing works
Lesogor, A., Cohn, J. N., Latini, R., Tognoni, G., Krum, H., Massie, B. M., Zalewski, A. A., Kandra, A., Hua, T. A., & Gimpelewicz, C. R. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft089 · Cited by 64 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [2]2. American Diabetes Association. Standards of medical care in diabetes-2018. Diabetes Care . 2018;41:S1-S159.
Cited by
Sorted by citations
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2022</i>
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344 · see citing works
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D. M., Johnson, E. L., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 300 · see citing works
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K. K., Lingvay, I., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 292 · see citing works
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 262 · see citing works
Kraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219 · see citing works
Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020050723 · Cited by 176 · see citing works
Self-citationOshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.042 · Cited by 166 · see citing works
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108 · see citing works
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
Meraz-Muñoz, A., Weinstein, J. J., & Wald, R. (2021) · Kidney360 · doi:10.34067/kid.0001172021 · Cited by 108 · see citing works
Carrero, J. J., & Elinder, C. G. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13418 · Cited by 90 · see citing works
on behalf of the ADVANCE Collaborative Group, Oshima, M., Jun, M., Ohkuma, T., Toyama, T., Wada, T., Cooper, M. E., Hadjadj, S., Hamet, P., Harrap, S. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4948-4 · Cited by 81 · see citing works
Self-citationCollard, D., Brouwer, T. F., Engberink, R. O., Zwinderman, A. H., Vogt, L., & van den Born, B. H. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14659 · Cited by 62 · see citing works
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 60 · see citing works
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, B. L., Tighiouart, H., Heerspink, H. J. L., Vonesh, E. F., Chaudhari, J., Miao, S., Chan, T. M., Fervenza, F. C., Floege, J., Goicoechea, M., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070948 · Cited by 36 · see citing works
Self-citationLoutradis, C., Price, A. M., Ferro, C. J., & Sarafidis, P. A. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00504-9 · Cited by 31 · see citing works
Fu, E. L., Trevisan, M., Clase, C. M., Evans, M., Lindholm, B., Rotmans, J. I., van Diepen, M., Dekker, F. W., & Carrero, J. J. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03060319 · Cited by 30 · see citing works
Renin-Angiotensin System Blockade in Advanced Kidney Disease: Stop or Continue?
Burnier, M. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.002 · Cited by 31 · see citing works
Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study
McCoy, I. E., Han, J., Montez‐Rath, M. E., & Chertow, G. M. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.038 · Cited by 30 · see citing works
Kidney disease trials for the 21st century: innovations in design and conduct
Herrington, W. G., Staplin, N., & Haynes, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0212-x · Cited by 25 · see citing works
Ku, E., Tighiouart, H., McCulloch, C. E., Inker, L. A., Adingwupu, O. M., Greene, T., Estacio, R. O., Woodward, M., de Zeeuw, D., Lewis, J. B., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000426 · Cited by 24 · see citing works
Self-citationAKI—A Relevant Safety End Point?
McCoy, I. E., & Chertow, G. M. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.11.010 · Cited by 20 · see citing works
Khan, M. S., & Lea, J. P. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03652-5 · Cited by 17 · see citing works
Jun, M., Harris, K., Heerspink, H. J. L., Badve, S. V., Jardine, M., Harrap, S. B., Hamet, P., Marre, M., Poulter, N. R., Kotwal, S. S., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14351 · Cited by 14 · see citing works
Self-citationChen, D. C., McCallum, W. I., Sarnak, M. J., & Ku, E. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01365-3 · Cited by 12 · see citing works
Naveed, H., Elshafeey, A., Al‐Ali, D., Janjua, E., Nauman, A., Kawas, H., Kaul, R., Aldien, A. S., Elshazly, M. B., & Zakaria, D. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1852 · Cited by 12 · see citing works
ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects
Vasudeva, K., Balyan, R., & Munshi, A. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08583-1 · Cited by 11 · see citing works
Olsen, E., Jamerson, K., Schmieder, R. E., Søraas, C. L., Mariampillai, J. E., Mancia, G., Kjeldsen, S. E., Heimark, S., Mehlum, M. H., Liestøl, K., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.021 · Cited by 9 · see citing works
Self-citationSud, M. K., Ko, D. T., Chong, A. S., Koh, M., Azizi, P., Austin, P. C., Stukel, T. A., & Jackevicius, C. A. (2021) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2624 · Cited by 8 · see citing works
Chan, Y., Chao, T., Chen, S., Kao, Y., Huang, C.-Y., & Chu, P. (2022) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcac040 · Cited by 7 · see citing works
Chen, J., Huang, K., Lin, Y., Chueh, S., Wang, H., & Wu, V. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad709 · Cited by 7 · see citing works
Narayan, P., Kumar, S., & Kapoor, L. (2022) · The Thoracic and Cardiovascular Surgeon · doi:10.1055/s-0042-1742685 · Cited by 5 · see citing works
Beaubien‐Souligny, W., Leclerc, S., Verdin, N., Ramzanali, R., & Fox, D. E. (2022) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221127940 · Cited by 5 · see citing works
Schytz, P. A., Bonde, A. N., Torp-Pedersen, C. T., Gislason, G., Nelveg-Kristensen, K. E., Hommel, K., Gerds, T. A., & Carlson, N. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002573 · Cited by 5 · see citing works
Ku, E., Jamerson, K., Copeland, T. P., McCulloch, C. E., Tighiouart, H., & Sarnak, M. J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035177 · Cited by 4 · see citing works
Wang, N., Chalmers, J. P., Harris, K., Poulter, N. R., Mancia, G., Harrap, S. B., Hamet, P., Grobbee, D. E., Marre, M., & Woodward, M. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003855 · Cited by 4 · see citing works
Self-citationGambaro, A., Lombardi, G., Ribichini, F. L., Mantovani, A., Bignamini, A. A., & Gambaro, G. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000003066 · Cited by 4 · see citing works
Observational analyses from ADVANCE and ADVANCE‐ON
Chalmers, J. P., & Woodward, M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13894 · Cited by 3 · see citing works
Self-citationShort-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality
Ohkuma, T., Harris, K., Cooper, M. E., Grobbee, D. E., Hamet, P., Harrap, S. B., Mancia, G., Marre, M., Patel, A. A., Rodgers, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00180122 · Cited by 3 · see citing works
Self-citationBeige, J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013145 · Cited by 3 · see citing works
Polypharmacy as a reason for misinterpreting laboratory results in the elderly
İncir, S., & Bolayirli, M. (2025) · Advances in pharmacology · doi:10.1016/bs.apha.2025.05.001 · Cited by 2 · see citing works
Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate
Ku, E., Tangri, N., Brar, R., McCulloch, C. E., & Sarnak, M. J. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.3680 · Cited by 2 · see citing works
Neue Aspekte der medikamentösen Nephroprotektion
Beimler, J. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01297-w · Cited by 2 · see citing works
Determining Factors Influencing RAS Inhibitors Re-Initiation in ICU: A Modified Delphi Method
Dahel, H., Lafrance, J., Patenaude, M., Kilpatrick, K., Beaubien‐Souligny, W., Moreau, M., & Wang, H. T. (2022) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221112266 · Cited by 2 · see citing works
Signorini, L. F., Zaza, G., & Gambaro, G. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa171 · Cited by 2 · see citing works
Maeda, T., Woodward, M., Jun, M., Sakamoto, Y., Chen, X., Matsushita, K., Mancia, G., Arima, H., Anderson, C. S., Chalmers, J. P., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003711 · Cited by 2 · see citing works
Self-citationYuan, S., Liu, Y., He, W., Jin, J., Liu, L., & He, Q. (2021) · Nephrology · doi:10.1111/nep.13915 · Cited by 1 · see citing works
Angiotensin converting enzyme inhibitors in nephrology
Chábová, V. Č. (2020) · Klinická farmakologie a farmacie · doi:10.36290/far.2019.030
Assadi, F. K. (2021) · World Journal of Pediatrics · doi:10.1007/s12519-021-00455-8
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch23
The Use of Antihypertensive Drugs in Patient with Chronic Kidney Disease: Priority Areas
Чак, Т. А., Романова, И. С., & Шевченко, О. О. (2022) · Рецепт · doi:10.34883/pi.2021.24.6.002
Myke-Mbata, B. K., Basil, B., Oloche, J. J., & Igbom, A. (2023) · PubMed Central
Complexities in Interpretation of Elevated Serum Creatinine
Ejaz, A. A., Patel, A. M., Browne, M. C., Fisher, E. I., Pournazari, K., & Seliger, S. L. (2025) · Blood Purification · doi:10.1159/000545122
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Miyazawa, I., Araki, S.-I., Yokoyama, H., Kume, S., & Maegawa, H. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109309
- Authors
- Ohkuma, T., Jun, M., Rodgers, A., Cooper, M. E., Glasziou, P., Hamet, P., Harrap, S., Mancia, G., Marre, M., Neal, B., Perkovic, V., Poulter, N., Williams, B., Zoungas, S., Chalmers, J., Woodward, M., & on behalf of the ADVANCE Collaborative Group
- Affiliations
- UNSW Sydney (AU)
- Monash University (AU)
- Bond University (AU)
- Centre Hospitalier de l’Université de Montréal (CA)
- The Royal Melbourne Hospital (AU)
- University of Milan (IT)
- Hôpital Bichat-Claude-Bernard (FR)
- Imperial College London (GB)
- UCL Biomedical Research Centre (GB)
- Johns Hopkins University (US)
- Corresponding author
- Rodgers, Anthony
- ORCID
- Venue
- Hypertension
- Published
- 2019-01
- Volume
- 73
- Issue
- 1
- Pages
- 84-91
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2901992834
- Cited by
- 56
- References
- 20
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 12 · 2021: 11 · 2020: 10 · 2019: 6
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Bond University Research Portal (Bond University) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Amgen (1080206)
- National Institute for Health and Care Research
- University of New South Wales
- Servier
- Medical Research Council (MC_PC_13090)
- National Health and Medical Research Council (1080206)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- ACE inhibitors, perindopril/indapamide, type 2 diabetes, diabetic nephropathy, all-cause mortality, ADVANCE trial, renin-angiotensin system blockade
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Drug Combinations, Female, Humans, Indapamide, Male, Middle Aged, Treatment Outcome, Drug Monitoring, Risk Assessment, Perindopril, Withholding Treatment, Medication Therapy Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
